Researchers are developing gene and cell therapies and prosthetics to help patients with blindness regain some vision. The first major prosthetic, the Argus II, was just discontinued. Where will the field go from here?
Researchers no longer think that proteins blindly swim through the cytoplasm hoping to bump into one another. Instead, they intentionally aggregate with other biomolecules, forming membrane free, transient organelles called condensates.
Philip Yeske was an organic chemist for more than 20 years, but when his daughter died from the rare mitochondrial disorder Leigh Syndrome, he turned to connecting researchers, patients, and law makers to speed the discovery of treatments.